|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
2.32/1.45
|
企业价值
1.87B
|
资产负债 |
每股账面净值
9.08
|
现金流量 |
现金流量率
0.12
|
损益表 |
收益
582.02M
|
每股收益
9.54
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 10:41 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX(pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |